Preemptive Antifungal Therapy for Febrile Neutropenic Hematological Malignancy Patients in China.
BACKGROUND The aim of this study was to evaluate the efficiency, adverse effects, and pharmacoeconomic impact of empirical and preemptive antifungal therapy for febrile neutropenic hematological malignancy patients in China. MATERIAL AND METHODS Patients with febrile neutropenia during hematological malignancy were randomly divided into an empirical group and a preemptive group. The preemptive antifungal treatment was initiated if patient status was confirmed by clinical manifestation, imaging diagnosis, 1-3-β-D glucan(G) testing, and galactomannan (GM) test. The treatment was ended 2 weeks later if the patient was recovered from neutropenia. Voriconazole was used as the first-line medicine. All patients received intravenous administration of voriconazole every 12 h, with an initiating dose of 400 mg, then the dose was reduced to 200 mg. RESULTS The overall survival rate was 97.1% and 94.6% in the empirical group and preemptive group, respectively, with no significant difference observed (χ²=1.051, P=0.305). However, the occurrence rate of invasive fungal disease (IFD) in the preemptive group was 9.2% vs. 2.2% in the empirical group. Moreover, the mortality rate due to IFD was 0.7% and 2.3% for the empirical group and preemptive group, respectively. The average duration and cost of preemptive antifungal therapy were 13.8±4.7 days and 8379.00±2253.00 RMB, respectively, which were lower than for empirical therapy. However, no significant differences were observed for incidence of adverse effects and hospital stay between the 2 groups. CONCLUSIONS Preemptive antifungal therapy for patients with febrile neutropenic hematological malignancy demonstrated a similar survival rate as with empirical therapy but is economically favorable in a Chinese population.
Department of Haematology, Pingan Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland).
Wei
W
Yuan
Department of Haematology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland).
Jinhai
J
Ren
Department of Haematology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland).
Xiaonan
X
Guo
Department of Haematology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland).
Xiaoling
X
Guo
Department of Haematology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland).
Shengxin
S
Cai
D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage*; D002681:China; D064147:Febrile Neutropenia / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D005260:Female; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000382:microbiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy / Q000378:metabolism / Q000517:prevention & control*; D015996:Survival Rate; D065819:Voriconazole / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D055815:Young Adult
D000935:Antifungal Agents; D065819:Voriconazole